Effect of periodontal treatment on rheumatoid arthritis

Not Applicable

• Conditions: Rheumatoid arthritis; Periodontal Disease; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12612000446864
• Lead Sponsor: niversity of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

All participants must have rheumatoid arthritis.

Willingness to participate and return for multiple visits; presence of gingivitis, mild, moderate or advanced chronic periodontitis, partially or fully dentate patients (at least 20 teeth); no evidence of known systemic modifiers of periodontal disease such as: type I and II diabetes mellitus, osteoporosis, disorders of cellular immunity (e.g. AIDS, cyclic neutropenia, or other known specific leukocyte defects which we know predisposes to periodontitis), medications known to influence the periodontal tissues, or any conditions that would contraindicate a periodontal examination (e.g. risk of bacterial endocarditis).

To be included in the RA group, all participants must have rheumatoid arthritis. Patients will need to indicate a willingness to participate and return for multiple visits and be partially or fully dentate patients (at least 20 teeth). Individuals with evidence of sicca symptoms will not be excluded because decreased salivary flow in these individuals is NOT a modifying or predisposing factor for the development or progression of periodontitis. RA patients will need to have low to moderate disease activity (DAS 2.6-5.1)

Exclusion Criteria

Patients who will not give informed consent; aggressive periodontitis, obvious endodontic infections or other sources of oral infection, pregnancy or lactating females; patients with a significant medical history indicating evidence of known systemic modifiers of periodontal disease as described above; patients who have taken prescribed systemic antibiotics in the last 3 months; patients who would need prophylactic antibiotics before any medical/dental procedures; patients who have received previous periodontal therapy. Smokers and individuals taking medications known to impact on gingival health will also be excluded as these individuals may have impaired responses to conservative periodontal therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified